Background
Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) remain the leading causes of morbidity and mortality in the United States. As of December 2004, an estimated 944 306 persons had received a diagnosis of AIDS of which more than half (529 113; 56%) have died. 1 Approximately 1.1 million people are currently infected with HIV in the United States, including 21% who are unaware of their positive status. 2 The New York City AIDS case rate (41/100 000 population) is more than 3 times the national average and is 45 times the Healthy People 2010 Goals. 3 Clearly, HIV/AIDS remains an important therapeutic area for pharmacists to remain updated.
Recently the Centers for Disease Control and Prevention (CDC) revised HIV-testing recommendations for pregnant women and patients in health care settings. These recommendations suggest that separate written consent for HIV testing should not be required and general consent for medical care should be considered sufficient to encompass consent for HIV testing. The objectives of these recommendations are to increase HIV screening, foster earlier detection of HIV infection, identify and counsel persons with unrecognized HIV infection, and provide them with access to medications and necessary services. 1 Medication access is extremely important because antiretroviral therapy (ART) has dramatically improved survival rates. 1, 4 The CD4 T-cell count (or CD4 count) serves as the major clinical indicator of immune function in HIV-infected patients. 5 A normal CD4 count for most laboratories ranges from 800 to 1050 cells/mm 3 . 6 Prior HIV treatment guidelines 7 recommended ART when the CD4 cell counts dropped below 200 cells/mm 3 . However, guidelines available at the time of this project recommended ART initiation in people with CD4 cell counts less than 350 cells/mm 3 or in people with CD4 cell counts >350 cells/mm 3 with specific conditions. 5 A recent landmark study 8 showed a statistically significant improved survival benefit (70%; P < .001) when ART was initiated at CD4 cell counts between 350 and 500 cells/mm 3 compared to the delay in treatment at CD4 cell counts <350 cells/mm 3 . The findings of this study encouraged providers to consider earlier initiation of ART in HIV-infected people. Additionally, the SMART study demonstrated that interruption of ART (ie, cessation of ART therapy when CD4 cell counts >350 cells/mm 3 and reinstitution of ART when CD4 cell counts dropped below 250 cells/mm 3 ) resulted in a greater risk of virologic failure. Uninterrupted ART results in better health and survival. 9, 10 In light of the recommendations to initiate ART earlier, it is likely that more patients will receive ART, resulting in increased numbers of ART prescriptions. The inappropriate use of these medications can lead to virologic failure, drug interactions, adverse drug reactions, and inappropriate dosing, potentially resulting in increased morbidity and mortality. It is therefore important that all pharmacists be knowledgeable about antiretroviral medications to reduce and prevent medication misadventures. A survey of pharmacists in Arizona conducted by Katz and colleagues in 1993 found that pharmacists felt prepared, comfortable, and possessed positive attitudes regarding the disease state, HIV/AIDS, but had limited knowledge of ART. 11 Our research study is the most recent evaluation of ART medication knowledge in New York State-(NYS) licensed pharmacists.
Study
The primary goal of this study was to assess antiretroviral medication knowledge of pharmacists licensed in NYS, a location with a relatively high HIV prevalence. The research The executive directors forwarded the survey to their members via a hyperlink (in e-mail or as part of a scheduled mailer with the URL provided) and invited them to participate only once using an electronic survey software package (SurveyMonkey 1 , LLC, www.SurveyMonkey.com). The survey questions were developed by the authors who have extensive knowledge of /experience with HIV/AIDS, using the Department of Health and Human Services (DHHS) guidelines, 5 evaluated by an external expert in the field, and pilot tested using pharmacy students in the final semester of their PharmD program (n ¼ 30). The purpose of the external review was to confirm question/ answer accuracy and assure that the questions were basic and not directed at experts in this area. The survey questions were divided into several sections including demographic information, educational background, pharmacology/therapeutic curricula specifically addressing antiretroviral topics, assessment of antiretroviral medication knowledge, pharmacy practice settings, and miscellaneous questions concerning membership in professional organizations and preferred methods of attaining continuing education.
Results
A total of 238 pharmacists responded to the survey (see Table 1 for demographic data and Table 2 for educational background and advanced certifications). More than half of the respondents identified hospital as their primary practice setting (112 of 220; 50.9%), the remaining respondents practice in community pharmacy (65 of 220; 29.5%), pharmacy industry (16 of 220; 7.3%), academia (14 of 220; 6.4%), nursing home (7 of 220; 3.2%), or in managed care (6 of 220; 2.7%). Although most practiced in an urban area (138 of 220; 62.7%), the majority responded that only 1% to 10% of their patients receive ART (150 of 220; 68.2%) and 11.4% (25 of 220) denied any exposure to patients on ART. More than half (125 of 225; 55.6%) had antiretroviral pharmacology as part of their curriculum and 90% remained current on this topic by using various educational modalities that is continuing education programs, journal articles, and other educational modalities.
More than half of the pharmacists (137 of 238; 57.6%) completed the entire survey. Interestingly, most of the participants that did not complete the survey stopped at the start of the antiretroviral knowledge-based questions. Knowledge-based questions varied greatly in correct responses. Only 62% (85 of 137) correctly identified a serious central nervous system side effect of efavirenz and only 59.1% (81 of 137) identified a potentially serious abacavir hypersensitivity reaction. Less than half (65 of 137; 47.4%) correctly identified a drug interaction between the concomitant use of esomeprazole and atazanavir and a contraindication with concurrent use of simvastatin and lopinavir/ritonavir (44 of 137; 32.1%). Only 38.7% (53 of 137) correctly identified the need for ''boosted'' combination therapy of darunavir with ritonavir and only 56.2% (77 of 137) correctly identified the concern of the teratogenic effects of efavirenz usage in pregnancy. More than two thirds (95 of 137; 69.3%) recognized the underdosing of zidovudine/lamivudine and 70.8% (97 of 137) correctly identified the appropriate administration of didanosine (ie, administer on an empty stomach). Lastly, almost all (131 of 137; 95.6%) were able to identify the drug interaction with concurrent use of St John's Wort and protease inhibitors (see Table 3 for all knowledge based questions included in the survey and percentage of correct responses). Our study had several limitations. First, a significant number of participants stopped completing the survey at the start of the antiretroviral knowledge questions. The authors propose that this may be attributed to the lack of familiarity with ART by such participants, which could actually indicate an even lower correct response rate than what is reported in this study. Second, our survey response rate is unknown, as we did not have access to actual rosters from the various organizations.
Finally, close to 80% of the pharmacists surveyed indicated that they were rarely (10% of patients) exposed to patients on ART, which may explain why these pharmacists are not as familiar with antiretroviral medications compared to other categories of pharmaceutical agents. This knowledge assessment may not accurately reflect the knowledge of pharmacists who work in HIV specialty pharmacies or pharmacists who see a high volume of HIV-infected patients. In future studies, we propose the use of a more accurate assessment of exposure to patients on ART, perhaps, looking at the total number of ART prescriptions dispensed each month.
Conclusion
As medication experts, pharmacists serve an important role in educating and protecting their HIV-positive patients. The results of our research revealed a lack of antiretroviral knowledge among pharmacists, particularly in the area of drug interactions, dosing and appropriate ART selection. The importance of this education is echoed by our survey participants, as more than half of the pharmacists (77 of 135; 57%) indicated that NYS should have mandatory continuing education (CE) focused on antiretroviral medications and HIV/AIDS topics and should be a part of re-registration similar to the mandatory CE topic, medication errors.
Addendum
Since the completion of this project and development of this manuscript, the DHHS has released a revised set of guidelines for the use of antiretrovirals in HIV-1 infected adults and adolescents. 12 Consistent with our expectations, the new DHHS guidelines continue to expand the number of HIV-infected patients for which they recommend antiretroviral therapy. The new guidelines state that antiretroviral therapy is recommended for HIV-infected patients with CD4 counts between 350 and 500 cells/mm 3 and can be considered for those with CD4 counts greater than 500 cells/mm 3 .
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